• An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus

  NCT06010472

  RecruitingInterventionalEarly Phase 1Updated Apr 29, 2025
• NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus

  NCT07083349

  Not yet recruitingInterventionalNot ApplicableUpdated Jul 28, 2025
• Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE

  NCT06892145

  RecruitingInterventionalPhase 1Updated Dec 22, 2025
• CD19/BCMA CAR-T for SLE

  NCT07266337

  Not yet recruitingInterventionalEarly Phase 1Updated Dec 5, 2025
• A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus

  NCT07339332

  RecruitingInterventionalEarly Phase 1Updated Jan 14, 2026
• SNC116 Therapy for Refractory Systemic Lupus Erythematosus

  NCT07748156

  Not yet recruitingInterventionalEarly Phase 1Updated Aug 5, 2026

ClinicalTrials.gov ID

NCT07358988

Lead Sponsor

Ruitherapeutics Co., LTDINDUSTRY

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 1

Enrollment

36Estimated

Last Update Posted

Jan 22, 2026Actual

Start Date

Jan 2026Estimated

Primary Completion Date

Jul 2027Estimated

Completion Date

Jul 2027Estimated

Official Title

A Multicenter Phase I Clinical Study of CD19-Targeted CAR-NK Cell Therapy for Moderate to Severe Active Systemic Lupus Erythematosus in China

Brief Summary

The goal of this clinical trial is to learn about the safety, pharmacokinetics and pharmacodynamics profile of KN5501 cell injection in adults with systemic lupus erythematosus(SLE). It will also learn if KN5501 cell injection works to treat refractory SLE. The main questions it aims to answer are:

1. Is KN5501 cell injection safe in adults with SLE? And the maximum tolerated dose?
2. Does KN5501 cell injection lower the disease activity of SLE in adults with refractory SLE？

Participants will:

Receive one or multiple (3 to 5 times) intravenous infusion of KN5501 cell injection at inpatient ward after lymphodepletion.

Visit the clinic at predefined frequency (from 1 week interval to 12-16 weeks' interval) for checkups and tests.

• Systemic Lupus Erthematosus (SLE)

• KN5501 cell injection

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• 1. Aged 18~70(including thresholds) when obtaining informed consent;
• 2. Body weight > 40.0 kg at screening;
• 3. Refractory SLE patients with moderate to severe activity;
• 4. CBC meeting predefined requirements at screening, including ANC ≥ 1.5×10^9/L, Hb ≥ 80g/L, and PLT ≥ 50×10^9/L(Not applicable, if it is ITP due to active SLE disease which is judged by investigator);
• 5. Adequate liver, kidney, lung and ;heart function at screening;
• 6. The date of last supportive therapy of hemopoietic growth factor(including EPO, G-CSF, GM-CSF and TPO, etc.)should be at least 2 weeks before screening visit, the last date of PLT infusion should be at least one week before screening visit, and the last date of RBC infusion should be at least 2 weeks before screening visit;
• 7. The number of CD19+ B cells in peripheral blood > 5 cells per microliter at screening;
• 8. Negative serum pregnancy test for WOCBPs at screening. Male or Female trial participants of child bearing potential should utilize efficient contraceptive measures from ICF signing until at least one year since the last dose, and promise not to donate ovums or sperms until at least one year since the last dose.

Exclusion Criteria:

• 1. Hypersensitive or allergic to any components of KN5501(e.g. DEXTRAN 40) or other trial interventions including fludarabine, cyclophosphamide, and tocilizumab, or having ever experienced severe anaphylaxis;
• 2. Severe lupus nephritis patients, defined as proteinuria ≥3.5g/24h or a history of renal replacement therapy. Or high risk of progressive LN disease which will probably require induced intensive treatment;
• 3. CNS affected, including but not limited to lupus encephalopathy, seizure, strock(ischemic or hemorrhagic), dementia, cerebellar disease, organic brain syndrome, encephalitis, CNS vasculitis, or mental disease;
• 4. Severe lung disease, e.g. pulmonary hypertension ≥ grade 3(WHO), or requiring mask oxygen therapy or ventilator-assisted breathing(non-invasive or invasive) ;
• 5. Unstable cardiovascular system, e.g. myocardial infarction within 6 months before screening, unstable angina within 3 months before screening, uncontrolled and clinically significant ventricular arrhythmia(including ventricular tachycardia, ventricular fibrillation, or TdP), second-degree atrioventricular block of Mobitz type II or third-degree atrioventricular block, congestive heart failure with New York Heart Association class ≥ 3; poorly controlled hypertension (SBP > 160 mmHg and/or DBP > 100 mmHg), or accompanied by hypertensive crisis or hypertensive encephalopathy;
• 6. Malignancy within 5 years before screening, excluding tumors with negligible risk of metastasis or death that are curable, such as radically treated non-melanoma skin cancer, localized prostate cancer, biopsy-confirmed cervical carcinoma in situ or squamous intraepithelial lesions detected by cervical smears, and completely resected ductal carcinoma in situ of the breast;
• 7. Severe infections requiring intravenous anti-infection treatment within 14 days before planned lymphodepletion, however preventive therapy is permitted;
• 8. Active or latent tuberculosis at screening;
• 9. HBV or HCV infection at screening. If positve HBsAg and/or HBcAb, HBV-DNA should be tested to confirm. If positive HCV-Ab, HCV-RNA should be tested to confirm;
• 10. Active HIV infection history, or positive serum HIV antigen or antibody test, or positive antibody test for Treponema Pallidum at screening.

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Sequential Assignment

Masking

None (Open Label)

Lead Sponsor

Ruitherapeutics Co., LTDINDUSTRY

tanwenfeng2005@126.com+86 13770769608